HIV protease inhibitor — competitive inhibition of HIV-1 aspartyl protease blocks gag/gag-pol polyprotein cleavage and prevents production of mature virions. Almost always coadministered with a CYP3A4 booster (cobicistat or ritonavir) for adequate exposure. Distinctive among PIs for its inhibition of UGT1A1 — causes asymptomatic Gilbert-like unconjugated hyperbilirubinemia in most users (visible as scleral icterus at high exposure); not hepatotoxic, doesn't require discontinuation. Requires acid for absorption — clinically significant interaction with PPIs / H2 blockers / antacids. Otherwise generally well tolerated long-term. PK (Reyataz label, boosted 300/100 mg PO qd with RTV at SS): Cmax 6129 ng/mL, AUC(0-24) 57039 ng·h/mL, Tmax ~2.5 h, t½ 9-18 h boosted (7-8 h unboosted). Light meal ↑ AUC ~33% + Cmax ~40% (food taken with dose). CL/F ≈ 5.3 L/h, V/F ≈ 91 L.
Half-Life & Elimination Curve (PO: 12h)
Plasma (PO)t½ Decay (12h)
0×t½0h100%(2.57 mg/L)
1×t½12h50%(1.28 mg/L)
2×t½24h25%(0.642 mg/L)
3×t½36h12.5%(0.321 mg/L)
4×t½48h6.3%(0.161 mg/L)
5×t½60h3.1%(80.3 µg/L)
Elimination t½12h (PO)
Rate Constant (ke)0.0578 h⁻¹
Time to Peak (Tmax)4.32h
Est. Peak (Cmax)2.57 mg/L
Clearance (CL)5.26 L/h
97% Washout (5×t½)60h
Dosing Guidelines
Oral (PO): Typical 300 mg (Range: 200–400 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 100% · Volume of Distribution (Vd): 91 L · Absorption (ka): 0.6 h⁻¹ (t½ka ≈ 1.16h)